Cetuximab, a monoclonal antibody against epidermal growth factor receptor, showed significant efficacy in locoregional control of disease and in overall survival either in the curative setting [6] or in the recurrent/metastatic HNSCC [7]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.